155 filings
8-K
OPNT
Opiant Pharmaceuticals Inc
2 Mar 23
Termination of a Material Definitive Agreement
9:20am
8-K
OPNT
Opiant Pharmaceuticals Inc
1 Mar 23
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
OPNT
Opiant Pharmaceuticals Inc
27 Feb 23
Departure of Directors or Certain Officers
4:04pm
8-K
OPNT
Opiant Pharmaceuticals Inc
7 Feb 23
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
4:26pm
8-K
OPNT
Opiant Pharmaceuticals Inc
9 Jan 23
Departure of Directors or Certain Officers
4:13pm
8-K
5qhagujqgb6
15 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
6s3y0fn
14 Nov 22
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
4:06pm
8-K
rf6 962a7
11 Aug 22
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
2u3sipx0uys 6rgt9jr
14 Jun 22
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
18oulbu
8 Jun 22
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
4:09pm
8-K
qmcyqz l0ioemkzz
10 May 22
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
qn9f9ydoj2 8yp
27 Apr 22
Other Events
4:06pm
8-K
b8ptpl4w
15 Mar 22
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
4:06pm
8-K
byxt9 i3qgo3hfx7oz6
7 Jan 22
Departure of Directors or Certain Officers
4:02pm
8-K
06y9ryhwxrw52c88 4jr
13 Dec 21
Departure of Directors or Certain Officers
4:01pm
8-K
a0ti67oaq9oco657 z4y
12 Nov 21
Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
8:03am
8-K
hgclv2d5 nuwq
8 Nov 21
Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
4:02pm
8-K
zam dj2cyknxcvni5ft
5 Aug 21
Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
r5zgtnc9
12 Jul 21
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
4:05pm
8-K
u0x isjb1gjbo
6 Jul 21
Other Events
4:03pm